Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
评价KL-A167注射液在复发或难治性鼻咽癌患者中的客观缓解率（ORR）
CTR20190152Phase 2Completed
- Sponsor
- Kelun-Biotech
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tagitanlimab in nasopharyngeal carcinoma (NPC), sponsored by Kelun-Biotech. Started Jan 2019; status: completed.
02
Drugs
tagitanlimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on CTR20190152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190152.